Related Experiment Video

Updated: May 15, 2025

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

1.2K

Omecamtiv Mecarbil in Systolic Heart Failure: Clinical Efficacy and Future Directions of a Novel Myosin-Activating

Mahmoud M Ramadan1,2, Abdullah L Alshawi2, Yasmeen A Mostafa2

  • 1Cardiology, Faculty of Medicine, Mansoura University, Mansoura, EGY.

Cureus
|May 13, 2025
PubMed

Insights

Omecamtiv mecarbil, a novel cardiac myosin activator, enhances heart contraction without increasing calcium. This review explores its potential to improve outcomes for patients with heart failure with reduced ejection fraction (HFrEF).

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure with reduced ejection fraction (HFrEF) is a significant global health issue with high morbidity and mortality.
  • Current guideline-directed therapies do not fully resolve symptoms in all HFrEF patients, particularly those with severely reduced ejection fraction.
  • Traditional inotropes have limitations in chronic HFrEF due to risks like arrhythmias and increased myocardial oxygen demand.

Purpose of the Study:

  • To review the pharmacologic profile and clinical trial data of omecamtiv mecarbil (OM).
  • To evaluate OM's potential as an adjunct therapy for advanced HFrEF.
  • To discuss OM's mechanism of action and safety profile in the context of HFrEF treatment.

Main Methods:

  • This is a narrative review synthesizing existing clinical trial data and pharmacologic information on omecamtiv mecarbil.
  • The review analyzes studies investigating OM's effects on cardiac function, exercise capacity, and clinical outcomes in HFrEF patients.
  • Safety data, including potential adverse effects and comparisons with traditional inotropes, are discussed.

Main Results:

  • Omecamtiv mecarbil activates cardiac myosin, enhancing systolic contraction by improving actin-myosin interaction efficiency.
  • OM prolongs systolic ejection time and increases stroke volume without raising intracellular calcium or myocardial energy consumption.
  • Clinical trials suggest OM does not significantly impair diastolic filling in most HFrEF patients, contrary to theoretical concerns.

Conclusions:

  • Omecamtiv mecarbil represents a novel therapeutic approach for HFrEF by targeting cardiac contractility.
  • While not yet guideline-recommended, OM shows potential as an adjunctive treatment for symptomatic HFrEF patients refractory to optimal therapy.
  • Further research and clinical integration of OM may offer a new option for managing advanced heart failure.

Keywords:
atomic-hfcardiac contractilitycosmic-hfgalactic-hfheart failureinotropic therapymeteoric-hfmyosin activatoromecamtiv mecarbilsystolic dysfunction

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.2K
Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice12:12

Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice

Published on: February 14, 2017

15.9K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
284
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
440
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
298